Loading
companiesCompany
Lunit
Korean AI company spanning mammography reading (INSIGHT MMG), breast-density risk (Volpara), and AI pathology for immunotherapy biomarkers.
Overview
21 studies at ECR 2026 covering INSIGHT MMG, Scorecard (ex-Volpara density), and INSIGHT CXR; a large Dutch randomised trial using Scorecard showed supplemental MRI in dense breasts reduced advanced cancer incidence. Lunit SCOPE pathology AI partnered with Labcorp and CellCarta (2025-26) for companion diagnostics.
Headquarters
Seoul, KR
Scorecard
All companies#362of 1244 companies, score 10
- approved products +6
- modalities +2
- regions +2
1 approved, 0 in phase 3, 0 earlier, 0 targets, 0 registry studies. Formula on the scorecards page.
Type
AI & software · 328130.KQ
Stage
Public
Website
ApprovedAI mammography detection software
Lunit INSIGHT MMG · Lunit INSIGHT MMG
A Korean AI mammography reader used in screening programmes in Sweden and Australia and cleared in the US and Europe.
Similar pages
- Key paperMASAI: AI-supported mammography screening finds more cancers with half the radiologist workload
Shares Roll out AI-supported mammography nationally as a stepped-wedge trial, Set each woman's mammogram interval from her last mammogram, using AI risk, Mammography & tomosynthesis, AI that is built but not validated or deployed.
- CompanyAidoc
Shares No clinical claims for imaging-derived biomarkers without phantom and standards compliance, AI clears the normal lung screening scans so radiologists read only the suspicious ones, AI-assisted central imaging reads to cut endpoint cost and variability, AI that is built but not validated or deployed.
- IdeaPathologist assistants plus AI triage to multiply pathologist capacity
Shares AI-first reading for high-volume common cancer diagnoses, pathologist for the exceptions, AI that is built but not validated or deployed, Not enough oncologists, nurses, pathologists, physicists, Digital pathology & AI.
- IdeaA dedicated fund for randomised trials of cancer AI with patient outcomes
Shares Mammography & tomosynthesis, AI that is built but not validated or deployed, AI in radiology, Digital pathology & AI.
- CompanyPaige AI
Shares AI-first reading for high-volume common cancer diagnoses, pathologist for the exceptions, Turn the map of immune cells inside a tumour into a standardised test, AI that is built but not validated or deployed, Not enough oncologists, nurses, pathologists, physicists.
- CompanyTherapixel
Shares Mammography & tomosynthesis, AI in radiology, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
- CompanyVara
Shares Mammography & tomosynthesis, AI in radiology, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
- TreatmentProFound AI (iCAD)
Shares Mammography & tomosynthesis, AI in radiology, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
cancers
fronts
technologies
drugs
ApprovedAI mammography detection software
Lunit INSIGHT MMG · Lunit INSIGHT MMG
companies
trials
ideas
AI clears the normal lung screening scans so radiologists read only the suspicious onesAI-assisted central imaging reads to cut endpoint cost and variabilityAI-first reading for high-volume common cancer diagnoses, pathologist for the exceptionsNo clinical claims for imaging-derived biomarkers without phantom and standards complianceRoll out AI-supported mammography nationally as a stepped-wedge trialSet each woman's mammogram interval from her last mammogram, using AI riskTurn the map of immune cells inside a tumour into a standardised test
bottlenecks
key papers
Software in use
The software of oncology →Commercial and regulated products that this organisation sells. Each card says what is behind it: a regulator's database, the literature, a public body's list, or only the company's own words. Listing is not endorsement, and a clearance is a regulatory fact, not a clinical one.
A family of reading algorithms sold into screening and diagnostic imaging: mammography, tomosynthesis and chest radiographs, each cleared separately.
Lunit's pathology side: algorithms that read stained slides for PD-L1 expression and for the immune phenotype of the tumour microenvironment.
Lunitno source outside the company found